Navigation Links
Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference
Date:9/29/2011

of OTO-104 (3 mg or 12 mg) or placebo. Patients were monitored over a three-month observation period following injection.  The study's primary objective was the evaluation of the safety and tolerability of OTO-104.  Additionally, the study evaluated various indicators of OTO-104 clinical activity including changes in vertigo, tinnitus, hearing function and patient quality of life.

"Following a meeting with the United States Food and Drug Administration regarding these Phase 1b results and our proposed plans for continued clinical development of OTO-104, we are now in a strong position to move this program forward," said David A. Weber, Ph.D., president and chief executive officer of Otonomy. "Importantly, our upcoming Phase 2 study will include a much greater number of patients and be powered to deliver statistically significant findings with regard to clinical efficacy.  As such, we look forward to the initiation of this study as we seek to establish the therapeutic potential of OTO-104 to help patients suffering from the debilitating symptoms of Meniere's disease."

About OTO-104OTO-104 is a sustained release formulation of the steroid dexamethasone that has been designed for intratympanic (IT) injection into the middle ear for the potential treatment of a broad range of inner ear disorders including vertigo, hearing loss and tinnitus.  OTO-104 is based on Otonomy's proprietary formulation technology which is intended to overcome the limitations associated with the use of unapproved short acting solutions in the ear.  These include limited drug exposure, large variability of delivered dose and the need for multiple IT injections.

About Meniere's DiseaseMeniere's disease is a disorder of the inner ear characterized by acute episodes of vertigo, fluctuations in hearing, tinnitus and aural fullness.  The underlying cause of Meniere's disease is unknown and there are currently no FDA-approved drug treatments. &
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Otonomy Introduces Scientific Advisory Board
2. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
3. Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
4. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
10. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
11. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... -- News Facts , As the ... to genome-based research for human health and disease, the ... bite out of oral cancer with its world-class research into ... with the help of state-of-the-art solution comprising block, ... , To fuel its cutting-edge cancer research, the institute has ...
(Date:9/23/2014)... , Sept. 23, 2014   GenoSpace , ... comprehensive suite of tools to enable the broad use ... announced that it has been awarded Phase I of ... from the National Institutes of Health (NIH) to enable ... Logo - http://photos.prnewswire.com/prnh/20140922/147649 ...
(Date:9/23/2014)... September 23, 2014 Dr. Williams says, ... book on healthcare offers a three phase process that ... healthcare delivery system that would go far beyond anything ... regarding the delivery of healthcare.” , “Every effort to ... failed to provide discernable progress throughout that system because ...
(Date:9/22/2014)... who were treated with a statin in the hospital ... likely to survive than those who were not, according ... . This study was conducted by the same researchers ... can improve survival in victims of ischemic stroke., Ischemic ... a blood vessel that blocks blood from reaching areas ...
Breaking Biology Technology:National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2
... The American Chamber of Commerce in Spain (AmChamSpain) ... Victor Grifols Roura, as the winner of its ... to recognize the international efforts of business leaders, ... responsible economic globalization. (Logo: http://photos.prnewswire.com/prnh/20110304/PH59473LOGO) ...
... -- Using minute graphite particles 1000 times smaller than the ... University hope to boost the efficiencyand profitabilityof solar power plants. ... more on rooftops, but they,re not necessarily the best solar ... they can use only a fraction of the sunlight that ...
... 2011 Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) ... preliminary assessment of the initial cohort of Tardive Dyskinesia ... (VMAT2), NBI-98854. Based on this data, the Company is ... the U.S. Food and Drug Administration (FDA). ...
Cached Biology Technology:The American Chamber of Commerce in Spain Awards the Global Business Leader Award 2011 to Victor Grifols Roura, President and CEO of Grifols 2The American Chamber of Commerce in Spain Awards the Global Business Leader Award 2011 to Victor Grifols Roura, President and CEO of Grifols 3Nanoparticles improve solar collection efficiency 2Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor 2Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor 3Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor 4
(Date:9/23/2014)... manufacture their own "antifreeze" proteins to survive in ... side effect, researchers funded by the National Science ... accumulate inside their bodies resist melting even when ... to be an undesirable consequence of the evolution ... University of Oregon doctoral student Paul Cziko, who ...
(Date:9/23/2014)... When the body forms new tissues during ... communicate with each other. For years, scientists believed ... researchers at Carnegie Mellon University and the University ... mechanical communication is equally if not more ... of the Proceedings of the National Academy ...
(Date:9/23/2014)... have scoured cow rumens and termite guts for microbes ... the production of next-generation biofuels, but some of the ... lower intestine, researchers report. , Their study , ... of Sciences , is the first to use biochemical ... human gut can digest fiber, breaking it down into ...
Breaking Biology News(10 mins):Antifreeze proteins in Antarctic fish prevent both freezing and melting 2Antifreeze proteins in Antarctic fish prevent both freezing and melting 3The mechanics of tissue growth 2Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3
... this morning showed the "tropical trio": Tropical Storm Karl ... central Atlantic, and a waning Hurricane Julia in the ... Category 4 Hurricane status, and is currently a Category ... shear, cooler sea surface temperatures and warmer cloud top ...
... Were our early mammalian ancestors vegetarians, vegans or ... of early mammalians because current fossil analysis provides too ... size of chips in tooth fossils can help determine ... Prof. Herzl Chai of Tel Aviv University,s School of ...
... 2010 For Immediate Release Scripps Research Institute Professor ... grant as part of a National Institutes of Health (NIH) ... DNA sequencing technologies, which could enable biomedical researchers and health ... With the new grant, funded by the NIH,s Human Genome ...
Cached Biology News:GOES-13 sees a weaker Hurricane Julia in the 'tropical trio' 2A chip off the early hominin tooth 2Scripps research team wins $5.1 million to develop DNA sequencing technology 2
...
... T4 DNA Ligase catalyzes the formation ... ATP between double-stranded DNAs with 3' hydroxyl ... DNA Ligase buffer optimizes ligation which can ... nucleic acids are not substrates for this ...
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Biology Products: